Background: There is limited real-world data on the efficacy and safety of combination programmed cell death protein-1 (PD-1) inhibitor, nivolumab and the cytotoxic T-lymphocyte antigen (CTLA-4) inhibitor ipilimumab.
INTRODUCTION
The cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibitor, ipilimumab and the anti-programmed death 1 (PD-1) antibodies pembrolizumab and nivolumab, have revolutionized the treatment of patients with metastatic melanoma. Response rates of 10-15% for ipilimumab monotherapy and up to 44% for anti-PD-1 antibodies have been reported across various clinical trials. 1 Combinatorial strategies of combining anti-PD-1 antibodies with ipilimumab are now being evaluated, supported by preclinical studies which have shown dual blockade synergistically improves antitumor responses. [2] [3] [4] Patients with metastatic melanoma treated with the combination of nivolumab and ipilimumab in early-phase clinical trials had impressive responses and survival rates, irrespective of BRAF mutation status, albeit increased grade 3 and 4 adverse events. [5] [6] [7] [8] In the landmark CheckMate067 trial, treatment-naïve patients with metastatic melanoma treated with the combination of nivolumab and ipilimumab reported higher response rates and a longer median progression free survival (PFS) than patients treated with nivolumab or ipilimumab alone. 9, 10 Based on these results, the combination of nivolumab and ipilimumab has been approved for treatment of metastatic melanoma by a number of regulatory bodies. However, treatment-related adverse events (TRAEs) of any grade were reported in 96% of patients treated with the combination. Grade 3/4 immune-related adverse events (irAEs) were significantly higher in patients treated with combination therapy (55% vs 27.3% with ipilimumab and 16.3% for nivolumab monotherapy) leading to treatment discontinuation in more than a third of patients. [9] [10] [11] There is limited data on the efficacy and safety of combination immunotherapy in the nonclinical trial setting to guide every day practice.
In this study, we report on the clinical efficacy and safety of the combination of ipilimumab and nivolumab in patients treated outside of a clinical trial setting. Our study includes patients with brain metastases, in addition to patients with other poor prognostic factors and those previously treated with immune checkpoint inhibitors in whom the benefit of this therapeutic regimen is still unclear.
METHODS
We retrospectively assessed the efficacy and toxicity of combined PFS was defined as time between date of commencement of therapy to date of progression or death, whichever occurred first. OS was determined as the time between the initiation of the combination therapy and date of death. Kaplan-Meier estimates of PFS and OS from commencement of anti-PD-1 therapy were calculated separately for patients grouped by previous treatment and compared using a log-rank test, where P-values ≤ 0.05 were considered to be statistically significant. The study was approved by individual institution ethics committees.
RESULTS

Patient demographics
A total of 45 patients who received combined immunotherapy with nivolumab and ipilimumab were identified between August 2016 and May 2017. Baseline demographic data are detailed in Table 1 . The median follow up after commencement of therapy was 8.7 months (range 0.33-25.9 months). The median age was 63 years (range 20-82 years); 67% were males and majority (87%) were of good performance status (ECOG 0-1). BRAF V600 mutations were detected in 38% of patients. Nearly all the patients had AJCC stage M1c disease (98%). At commencement of treatment, 14 (31%) patients had brain metastases, 51% had an elevated LDH, 18 (40%) patients were treatment-naïve and almost a third (30%) of patients required corticosteroids >10 mg/day prednisolone or its equivalent for symptom control or management of prior toxicities, with doses ranging from dexamethasone 2-8 mg or an equivalent alternative corticosteroid. Nineteen (42%) patients had prior anti-PD-1 therapy, 14 (78%) received pembrolizumab and four (22%) patients had nivolumab. Of the patients that had prior pembrolizumab, three patients received ipilimumab first. All but one patient with BRAF V600 mutations had dabrafenib and trametinib as first line treatment.
Efficacy
The median interval between prior systemic therapy for metastatic disease and the first dose of combination therapy with ipilimumab and nivolumab was 31 days (range 0-1208 days). Twenty-eight patients (62%) received all four doses of combined nivolumab/ipilimumab. For patients that received all four doses of combination therapy, the median number of cycles of nivolumab monotherapy received was 8, with 53% still on treatment.
Of those enrolled, 42 patients were included in the final analysis. Efficacy data are summarized in Table 2 . The DCR was 54% and ORR was 29%, with three (7%) patients achieving a CR and nine (21%) achieving a PR. Patients that had received prior immune checkpoint inhibitors, that is ipilimumab and/or anti-PD-1 agents had an ORR 33% (with all responses being PR) and a DCR 50%. In treatment-naïve patients, the DCR was 56% and ORR was 24%. Of the 14 patients with brain metastases, 11 were evaluated for intracranial responses.
Intracranial responses were observed in 18% (n = 2) and disease control was achieved in five (45%) patients; six (55%) had progressive disease on imaging and/or clinically. The DCR in patients treated with the combination after progression on prior anti-PD-1 therapy was only 33%. The median OS was 17.4 months (95% CI, 7.1-NR; Figure 1 ). The median OS for patients not previously treated with anti-PD1 therapy was higher than patients previously exposed to immunotherapy (17.4 months vs 7.3 months, P = 0.06). Similarly, the median OS for treatment-naïve patients with brain metastases was higher than patients with brain metastases who received any prior local treatment (NR vs 1.8 months, P = 0.01). The median OS of patients on corticosteroids was significantly shorter than those not on corticosteroids (7.1 months vs NR, P = 0.01).
Toxicity
TRAEs of any grade were experienced by 88% of patients, with more than half (54%) experiencing grade ≥3 adverse events. The most common toxicity of any grade was fatigue, observed in 56%. In 44% of cases treatment was discontinued due to adverse events. The most common high-grade AEs was diarrhea or colitis (27%); other grade 3/4 irAEs were hepatitis, pneumonitis and dermatological toxicities. Four patients experienced two high-grade irAEs simultaneously (pneumonitis and rash, hepatitis and rash, pneumonitis and myocarditis, colitis and nephritis) and one patient had three simultaneous irAEs, hepatitis, rash and colitis. Two patients who experienced high-grade toxicity (colitis and hepatitis) with prior immunotherapy had recurrence of these toxicities when treated with combination immunotherapy. There were no treatment-related deaths. No treatment 1 (7) ECOG PS, Eastern Cooperative Oncology Group Performance Status; WBRT, whole brain radiation therapy. a One patient received nivolumab in the adjuvant setting and therefore not included. CR, complete response; DCR, disease control rate; NE, not evaluable; ORR, overall response rate; PR, partial response; SD, stable disease.
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Response
DISCUSSION
This study provides a unique insight into the efficacy and safety of combination ipilimumab and nivolumab in a patient population seen routinely in clinical practice, but often excluded from clinical trials. We observed lower objective responses in comparison to other studies, 9, 12 which could be explained by the large proportion of patients with elevated LDH levels, as well as by the inclusion of patients who had received prior treatment with checkpoint inhibitors and those with brain metastases, including symptomatic brain metastases requiring corticosteroids. The ORR in patients treated with the combination after progression on prior anti-PD-1 therapy was 33%, which is comparable to a recently reported study 12 and higher than observed with single-agent ipilimumab post-anti-PD1 treatment. 13 As shown by Zimmer et al. 12 response to prior anti-PD-1 therapy did not predict response to subsequent therapy.
The rates of TRAEs including grade 3/4 irAEs reported in this study were similar to that reported in the pooled analysis of trials evaluating combination nivolumab and ipilimumab (CA209-004, CheckMate 067, and CheckMate069). 14 Because of the retrospective nature of this study, safety data were not collected in a standardized manner that could have led to underreporting of toxicity. In addition, a large proportion of patients in this study were on corticosteroids at commencement of treatment. However, the toxicity profiles were similar, with the most commonly reported grade 3/4 irAEs being diarrhea/colitis. All toxicities were treated with high-dose immunosuppressive therapies as per standardized algorithms. The KEYNOTE 029 study showed comparable durable antitumor activity with standard-dose pembrolizumab plus reduced-dose ipilimumab (1 mg/kg ipilimumab in comparison to 3 mg/kg used in the Checkmate067), however reported a lower number of grade 3/4 irAEs and patients discontinuing therapy for TRAEs. 15 In our study, the intracranial ORR was lower compared to two recently reported phase II trials, 16, 17 but similar to a study evaluating anti-PD1 antibodies in melanoma patients with brain metastases. 18 The CheckMate204 
CONCLUSION
In conclusion, our study demonstrates impressive response rates in patients treated with combination nivolumab and ipilimumab with a toxicity profile similar to those seen in clinical trials. In this study patients pretreated with immune checkpoint inhibitors had an similar response rates compared to treatment-naive patients. Trials are underway evaluating the role of combination ipilimumab and pembrolizumab/nivolumab post-anti-PD1. Till results from these trials become available, the benefit of a combination approach after anti-PD1 failure is still unclear. Furthermore more mature survival data from the Checkmate067 study is required to confidently identify patients most likely to benefit from this combinatorial approach.
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